{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:06:44Z","timestamp":1790150804050,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15530-w","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:54:15Z","timestamp":1783918455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recombinant zoster vaccine uptake and series completion among immunocompromised adults with cancer in the US"],"prefix":"10.1186","volume":"26","author":[{"given":"Justin","family":"Gatwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"McGuiness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasudha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Stempniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"15530_CR1","unstructured":"National Cancer Institute. Cancer Stat Facts: Cancer of Any Site. https:\/\/seer.cancer.gov\/statfacts\/html\/all.html. Accessed 1 Apr 2025."},{"issue":"1","key":"15530_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","volume":"22","author":"LA Habel","year":"2013","unstructured":"Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82\u201390.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"48","key":"15530_CR3","doi-asserted-by":"publisher","first-page":"e8746","DOI":"10.1097\/MD.0000000000008746","volume":"96","author":"J Mao","year":"2017","unstructured":"Mao J, McPheeters JT, Finelli L. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study. Med (Baltim). 2017;96(48):e8746.","journal-title":"Med (Baltim)"},{"issue":"9","key":"15530_CR4","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988\u20131000.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"15530_CR5","doi-asserted-by":"publisher","first-page":"e3210","DOI":"10.1093\/cid\/ciaa1185","volume":"73","author":"RR Thompson","year":"2021","unstructured":"Thompson RR, Kong CL, Porco TC, Kim E, Ebert CD, Acharya NR. Herpes zoster and postherpetic neuralgia: changing incidence rates from 1994 to 2018 in the United States. Clin Infect Dis. 2021;73(9):e3210\u20137.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"15530_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.31909","volume":"125","author":"P Vink","year":"2019","unstructured":"Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer. 2019;125(8):1301\u201312.","journal-title":"Cancer"},{"issue":"2","key":"15530_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, L\u00f3pez-Jim\u00e9nez J, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial. JAMA. 2019;322(2):123\u201333.","journal-title":"JAMA"},{"issue":"3","key":"15530_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","volume":"71","author":"TC Anderson","year":"2022","unstructured":"Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, et al. Use of recombinant zoster vaccine in immunocompromised adults aged\u2009\u2265\u200919 years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"15530_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"15530_CR10","unstructured":"Centers for Disease Control and Prevention (CDC). Clinical considerations for Shingrix use in immunocompromised adults aged\u2009\u2265\u200919 years. https:\/\/www.cdc.gov\/shingles\/hcp\/vaccine-considerations\/immunocompromised-adults.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/immunocompromised-adults.html. Accessed 1 Apr 2025."},{"issue":"35","key":"15530_CR11","first-page":"BPI22","volume":"20","author":"A Jorga","year":"2022","unstructured":"Jorga A, Friedland LR, Lecrenier N, Safonova E, Vink P, Widenmaier R. BPI22-019: Guidelines and recommendations for the adjuvanted recombinant zoster vaccine in immunocompromised cancer patients. J Natl Compr Canc Netw. 2022;20(35):BPI22\u2013019.","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"15530_CR12","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(14):1699\u2013721.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15530_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vaccine.2022.10.076","volume":"41","author":"J Fix","year":"2023","unstructured":"Fix J, Vielot NA, Lund JL, Weber DJ, Smith JS, Hudgens MG, et al. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50\u201364 years old in the United States. Vaccine. 2023;41(1):49\u201360.","journal-title":"Vaccine"},{"issue":"5","key":"15530_CR14","doi-asserted-by":"publisher","first-page":"ofae211","DOI":"10.1093\/ofid\/ofae211","volume":"11","author":"ZA Marcum","year":"2024","unstructured":"Marcum ZA, Jain P, Embry A, Arakaki B, Estevez I, Viscidi E. Incidence of herpes zoster and postherpetic neuralgia and herpes zoster vaccination uptake in a US administrative claims database. Open Forum Infect Dis. 2024;11(5):ofae211.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"15530_CR15","first-page":"S151","volume":"12","author":"J Gatwood","year":"2025","unstructured":"Gatwood J, McGuiness CB, Yasuda M, Chen C-C, Stempniewicz N. Recombinant zoster vaccine uptake among immunocompromised US adults [Abstract P-29]. Open Forum Infect Dis. 2025;12(Suppl 1):S151.","journal-title":"Open Forum Infect Dis"},{"key":"15530_CR16","unstructured":"Center for Health Disparities Research. About the Neighborhood Atlas\u00ae. https:\/\/www.neighborhoodatlas.medicine.wisc.edu. Accessed 9 Dec 2024."},{"issue":"33","key":"15530_CR17","first-page":"729","volume":"63","author":"CM Hales","year":"2014","unstructured":"Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR, Centers for Disease Control and Prevention. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63(33):729\u201331.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"15530_CR18","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1016\/j.vaccine.2023.04.067","volume":"41","author":"CY Lewis","year":"2023","unstructured":"Lewis CY, Mishra K, Sun Y, Sechrist SJ, Arnold BF, Acharya NR. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data. Vaccine. 2023;41(23):3493\u20136.","journal-title":"Vaccine"},{"key":"15530_CR19","unstructured":"Jatlaoui TC, Hung MC, Srivastav A, Lu PJ, Black CL, Lindley MC, et al. Vaccination coverage among adults in the United States, National Health Interview Survey, 2019\u20132020. https:\/\/www.cdc.gov\/adultvaxview\/publications-resources\/vaccination-coverage-adults-2019-2020.html. Accessed 1 Apr 2025."},{"issue":"3","key":"15530_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","volume":"70","author":"PJ Lu","year":"2021","unstructured":"Lu PJ, Hung MC, Srivastav A, Grohskopf LA, Kobayashi M, Harris AM, et al. Surveillance of vaccination coverage among adult populations - United States, 2018. MMWR Surveill Summ. 2021;70(3):1\u201326.","journal-title":"MMWR Surveill Summ"},{"key":"15530_CR21","first-page":"1","volume":"370","author":"EP Terlizzi","year":"2020","unstructured":"Terlizzi EP, Black LI. Shingles vaccination among adults aged 60 and over: United States, 2018. NCHS Data Brief. 2020;370:1\u20138.","journal-title":"NCHS Data Brief"},{"key":"15530_CR22","unstructured":"Hung MC, Srivastav A, Lu PJ, Black CL, Lindley MC, Singleton JA. Vaccination coverage among adults in the United States, National Health Interview Survey, 2022. https:\/\/www.cdc.gov\/adultvaxview\/publications-resources\/adult-vaccination-coverage-2022.html. Accessed 1 Apr 2025."},{"key":"15530_CR23","doi-asserted-by":"publisher","first-page":"127326","DOI":"10.1016\/j.vaccine.2025.127326","volume":"60","author":"CT Hung","year":"2025","unstructured":"Hung CT, Wang LM, Liu DC. National trends and disparities in herpes zoster vaccination coverage among U.S. older adults with cancer, 2008\u20132023. Vaccine. 2025;60:127326.","journal-title":"Vaccine"},{"issue":"4","key":"15530_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.amepre.2021.03.023","volume":"61","author":"K Kawai","year":"2021","unstructured":"Kawai K, Kawai AT. Racial\/ethnic and socioeconomic disparities in adult vaccination coverage. Am J Prev Med. 2021;61(4):465\u201373.","journal-title":"Am J Prev Med"},{"key":"15530_CR25","first-page":"S172","volume":"38","author":"D Singer","year":"2023","unstructured":"Singer D, Evans K, Stempniewicz N, Page V, Huse S, Berger A. Disparities in recombinant zoster vaccine coverage among adults in the United States by race and ethnicity and social determinants of health [abstract]. J Gen Intern Med. 2023;38:S172.","journal-title":"J Gen Intern Med"},{"issue":"50","key":"15530_CR26","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.1016\/j.vaccine.2022.10.065","volume":"40","author":"J Leung","year":"2022","unstructured":"Leung J, Gray EB, Anderson TC, Sharkey SM, Dooling K. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50\u201364 years in the United States. Vaccine. 2022;40(50):7187\u201390.","journal-title":"Vaccine"},{"issue":"15","key":"15530_CR27","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1016\/j.vaccine.2022.03.006","volume":"40","author":"J LaMori","year":"2022","unstructured":"LaMori J, Feng X, Pericone CD, Mesa-Frias M, Sogbetun O, Kulczycki A. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017\u20132021. Vaccine. 2022;40(15):2266\u201373.","journal-title":"Vaccine"},{"key":"15530_CR28","doi-asserted-by":"crossref","unstructured":"Patterson BJ, Chen CC, McGuiness CB, Ma S, Glasser LI, Sun K et al. Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis. J Am Pharm Assoc (2003). 2022;62(2):526\u2009\u2013\u200936.e10.","DOI":"10.1016\/j.japh.2021.11.010"},{"issue":"8","key":"15530_CR29","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1080\/21645515.2021.1879579","volume":"17","author":"BJ Patterson","year":"2021","unstructured":"Patterson BJ, Chen CC, McGuiness CB, Glasser LI, Sun K, Buck PO. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019. Hum Vaccin Immunother. 2021;17(8):2482\u20137.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"15530_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/pop.2023.0284","volume":"27","author":"D Singer","year":"2024","unstructured":"Singer D, Sweeney C, Stempniewicz N, Reynolds M, Garbinsky D, Poston S. Knowledge, attitudes, and practices regarding herpes zoster vaccination among specialists. Popul Health Manag. 2024;27(4):231\u201340.","journal-title":"Popul Health Manag"},{"key":"15530_CR31","unstructured":"United States Census Bureau. DP1. Profile of general population and housing characteristics. https:\/\/data.census.gov\/table?q=race&g=010XX00US&d=DEC+Demographic+Profile. Accessed 22 Sep 2025."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15530-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15530-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15530-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:33:20Z","timestamp":1790148800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15530-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15530"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15530-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JG and NS are employed by, and hold financial equities in, GSK. JG also reports receipt of grants from Merck & Co. and AstraZeneca, consulting fees from Merck & Co. and Janssen, and conference travel reimbursement from Genentech outside the submitted work during the past 3 years. CM, VG, MY and CCC declare being employees of IQVIA which received funding from GSK to conduct the current study. IQVIA also conducts research projects funded by and in collaboration with the pharmaceutical industry. CM also holds financial equities in Pfizer. The authors declare no other financial and non-financial relationships and activities.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1134"}}